Denise Rezende: What Should Clinicians Do When Thrombosis Occurs Despite DOAC Therapy?
Denise Rezende, Product Manager of Systems Worldwide Marketing, Hemostasis at Werfen North America, shared a post on LinkedIn:
”Great topic and a very relevant discussion!
What should clinicians do when thrombosis occurs despite DOAC therapy?
Looking forward to hearing the perspectives of international experts and learning more about the clinical management and different approaches to these challenging situations.
Another great educational initiative supported by Werfen.”
Werfen shared a post on LinkedIn:
”What should clinicians do when thrombosis occurs despite DOAC therapy?
Join the upcoming ISTH webinar, ‘Breakthrough Thrombosis in DOACs: What to do Next,’ where international experts will explore the latest perspectives on managing these challenging cases.
August 19, 2026 | 12:00 PM UTC
Werfen is proud to support educational initiatives that advance understanding in thrombosis and hemostasis.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice
-
Nov 15, 2026, 15:03Francesco Antonio Veneziano: Rethinking Coronary Artery Disease Through Precision Cardiology
-
Nov 15, 2026, 14:37Denise Rezende: 100 Years of von Willebrand Disease and Advances in Diagnosis